Black cohosh fails phase III trial.
Black cohosh, a popular herbal remedy, failed to reduce hot flashes in a randomized, double-blind, placebo-controlled, phase III crossover trial presented in another poster at the meeting.
Barbara Pockaj, M.D., and her colleagues reported that the average decrease in hot flash scores was larger in placebo users (27%) than in those who received 20 mg of black cohosh daffy (20%).
At the end of the 9-week study, 36 (37%) of the 97 patients completing the study preferred placebo, 31 patients (32%) favored black cohosh, and 30 patients (30%) had no preference. The other 19 patients evaluated in the study were listed as missing. The study included breast cancer patients and women with a perceived risk of breast cancer.
Toxicity results gave a slight edge to black cohosh, with no adverse events reported by 87% of patients on the herbal remedy and 77% on placebo.
None of the findings reached statistical significance, Dr. Pockaj of the Mayo Clinic in Scottsdale, Ariz., said in an interview.
|Printer friendly Cite/link Email Feedback|
|Publication:||Family Practice News|
|Article Type:||Brief Article|
|Date:||Jul 15, 2005|
|Previous Article:||Hot flash trials compare venlafaxine, clonidine, and MPA.|
|Next Article:||Women may resist Pap + HPV testing: clinical staff should discuss testing before patient is seen by the doctor.|